Table 4.

Aurora B inhibitors in clinical trials ¹.

Compound	Clinical Trials	Current Status	Conditions	Interventions	Outcomes 2	Refs.
AZD1152 (Barasertib)	10 Clinical trials	Phase I/II 8 Completed 2 Terminated	Lymphoma, Advanced Solid Tumors, Acute Myeloid Leukemia	Monotherapy	Best response was CR for acute myeloid leukemia, and PR for lymphoma and acute myeloid leukemia	[112,113,114,115,116,117,118,119]
				Combination with low dose of Cytarabine, Venetoclax, Azacitidine	Best response was CR and PR for acute myeloid leukemia in combination with low dose of Cytarabine
BI-831266	NCT00756223	Phase I Completed	Advanced Solid Tumors	Monotherapy	Best response was PR for cervical cancer	[121]
BI-811283 (Structure Undisclosed)	NCT00701324	Phase I Completed	Solid Tumors	Monotherapy	Best response was SD	[123]
	NCT00632749	Phase II Completed	Acute Myeloid Leukemia	Combination with Cytarabine	Best responses were CR, PR, and CRi	[124]
Chiauranib	7 Clinical trials	Phase I/II 2 Completed 1 Terminated 3 Recruiting/ Planned 1 Ongoing	Ovarian Cancer, Non-Hodgkin’s Lymphoma, Hepatocellular Carcinoma, Small Cell Lung Cancer, Other Advanced Solid Tumors	Monotherapy	Best response was SD	[126]

¹ Data collected from clinicaltrials.gov. ² CR, complete remission; Cri, complete remission with incomplete blood count remission; PR, partial response; SD, stable disease.